Human Monoclonal Antibody Against Staphylococcus aureus Alpha Toxin in Mechanically Ventilated Adult Subjects (SAATELLITE) is a Phase II, randomized, double-blind, placebo-controlled trial. Involving patients who are at high risk of developing ventilator-associated pneumonia in an intensive-care unit. The trial will test the safety, the pharmacokinetic and pharmacodynamic characteristics, and the efficacy of MEDI4893. A novel treatment that uses antibodies against S. aureus.
The power of antibodies
MEDI4893, developed by AstraZeneca, is a promising monoclonal antibody against S. aureus alpha toxin. The toxin kills cells in patients and damages tissues and organs, which helps microbes to spread and cause serious infections and disease. MEDI4893 uses an antibody – not an antibiotic – against this alpha toxin. Prevention would work against S. aureus, regardless of whether this bug is resistant to antibiotics. Another benefit is that this antibody approach is not expected to lead to new antibiotic resistance.
Study team members
Contract Manager / Academic / CHU Limoges
Principal Scientist / EFPIA / MedImmune
Principal Investigator / Academic leader / CHU Limoges
Study level information
- Study NO NCT02296320
- Study Name SAATELLITE
- Study Type Phase II
- Study Status Database Lock
- Enrollment Period 10/14 - 12/18
- Total subjects planned 285
- Total subjects screened 767
- Total subjects enrolled 213
- Total subjects completed 213
- Light blue
- Preparation phase
- Dark blue
- Trial period
Country level information
Rapid Evolution and Host Immunity Drive the Rise and Fall of Antibiotic Resistance During Acute Infection
Antibiotic resistance poses a serious threat to human health. Resistant infections now cause more than 750,000 deaths per year and are predicted to in...
SAATELLITE Results Published in Lancet Infectious Diseases
The SAATELLITE study team is thrilled to announce the manuscript entitled “Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus...